Statin (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor)-based therapy for hepatitis C virus (HCV) infection-related diseases in the era of direct-acting antiviral agents.

Kishta, Sara Sobhy; Kishta, Sobhy Ahmed; El-Shenawy, Reem

Kishta, Sara Sobhy; Kishta, Sobhy Ahmed; El-Shenawy, Reem.

Afiliación

Kishta SS; Medical Biotechnology Lab, Microbial Biotechnology Department, National Research Center, Egypt, Cairo, Egypt.
Kishta SA; Department of Surgery, Theodor Bilharz Research Institute, Giza, Egypt.
El-Shenawy R; Medical Biotechnology Lab, Microbial Biotechnology Department, National Research Center, Egypt, Cairo, Egypt.

F1000Res ; 5: 223, 2016.

Article en En | MEDLINE | ID: mdl-27583130

Palabras clave

HCV infection-related diseases; Hepatitis C virus (HCV) infection; direct-acting antiviral agents (DAAs); human hepatocyte-like cells from human induced pluripotent stem cells; replicon system; statins

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google